Related Experiment Videos
New drugs in non-Hodgkin's lymphoma
S G Arbuck1, J M Sorensen, M C Christian
1Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
Abstract:
While novel agents designed to target molecular abnormalities involved in lymphoma pathogenesis are most likely to improve current therapeutic results, cytotoxic therapy remains the main-stay of therapy. Several new chemotherapy agents, including purine antimetabolites, taxanes, camptothecins, suramin, and protein kinase C inhibitors, are discussed. Other issues important in lymphoma drug development, including the limited patient population available for evaluation of investigational agents, are also considered.
Insights
Cytotoxic chemotherapy is the primary treatment for lymphoma, despite ongoing research into novel molecularly targeted agents. This review discusses new chemotherapy drugs and challenges in lymphoma drug development, such as small patient populations.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Cytotoxic chemotherapy is the current standard of care for lymphoma.
- Novel agents targeting molecular abnormalities show promise for improved therapeutic outcomes.
- Lymphoma drug development faces challenges, including limited patient populations for clinical trials.
Purpose of the Study:
- To review current and emerging chemotherapy agents for lymphoma treatment.
- To discuss challenges in the development of new lymphoma drugs.
- To highlight the role of cytotoxic therapy alongside novel agents.
Main Methods:
- Literature review of recent advancements in lymphoma chemotherapy.
- Discussion of specific drug classes: purine antimetabolites, taxanes, camptothecins, suramin, and protein kinase C inhibitors.
- Consideration of practical issues in clinical trial design for investigational lymphoma agents.
Main Results:
- Several new chemotherapy agents are under investigation for lymphoma.
- Purine antimetabolites, taxanes, camptothecins, suramin, and protein kinase C inhibitors represent promising therapeutic options.
- Patient population size is a significant factor impacting drug evaluation.
Conclusions:
- Cytotoxic therapy remains fundamental in lymphoma treatment.
- The development of novel agents is crucial for advancing lymphoma therapeutics.
- Addressing challenges in drug development, like patient recruitment, is essential for future progress.